{
    "organizations": [],
    "uuid": "8354077a4aa510e33808e1aa16a33d52b98cf679",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-santhera-pharmaceuticals-holding-2/brief-santhera-pharmaceuticals-holding-2017-revenues-from-sales-of-raxone-up-at-chf-22-9-million-idUSFWN1PN01U",
    "ord_in_thread": 0,
    "title": "BRIEF-Santhera Pharmaceuticals Holding 2017 Revenues From Sales Of Raxone Up At CHF 22.9 Million",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 29 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG :\n* INCREASE OF 21% YOY IN FY NET REVENUES TO CHF 22.9 MILLION (2016: CHF 19.0 MILLION) FROM SALES OF RAXONE\n* FOR 2017, SANTHERA ANTICIPATES A NET RESULT OF CHF -50 TO -55 MILLION.\n* FOR 2018 EXPECTS NET SALES OF RAXONE FOR CURRENTLY APPROVED INDICATION LHON TO REACH CHF 28 TO 30 MILLION Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-01-29T14:06:00.000+02:00",
    "crawled": "2018-01-30T19:11:06.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "santhera",
        "pharmaceutical",
        "holding",
        "ag",
        "increase",
        "yoy",
        "fy",
        "net",
        "revenue",
        "chf",
        "million",
        "chf",
        "million",
        "sale",
        "raxone",
        "santhera",
        "anticipates",
        "net",
        "result",
        "chf",
        "million",
        "expects",
        "net",
        "sale",
        "raxone",
        "currently",
        "approved",
        "indication",
        "lhon",
        "reach",
        "chf",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}